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Available online 15 September 2016MicroRNAs (miRNAs) are a class of endogenous and non-coding single-stranded RNAs of approximately 22 nu-
cleotides, many ofwhich are evolutionarily conserved. Genome-wide association studies have identiﬁed a robust
statistical association between theMIR137 gene and schizophrenia in Europeans,whichwas replicated in theHan
Chinese population in a case-control study. In the previous study, we provided evidence for a signiﬁcant associ-
ation between the EFNB2 gene and schizophrenia inHan Chinese subjects. In the current study, we utilized com-
putational analysis, vector construction of point mutations, luciferase reporter assays and gene expression assays
including RT-qPCR and western blotting methods to investigate miR-137 directly targeting EFNB2 gene and ex-
plore the reversal effect of a genetic variant of SNP rs550067317 in the putative seed-pair region of EFNB2 3′-
UTR.We also found that miR-137 could be detected in the peripheral blood of a cohort of ﬁrst-onset schizophre-
nia patients and healthy controls, and the area under curve was 0.795 (95% conﬁdence interval 0.700–0.890),
which is a middle diagnostic value for disease, suggesting that it might be valuable for diagnosing schizophrenia.
In summary, this studywould improve our understanding of the role ofmiR-137 in schizophrenia-associated sig-
naling pathways and identify the genetic basis of rs550067317 for schizophrenia. Furthermore, we provided new
evidence for the involvement of miR-137 in the etiology and diagnosis of schizophrenia, whichmight contribute
to the discovery of new biomarkers and therapeutic targets for the disease.
© 2016 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Regulation1. Introduction
MicroRNA (miRNAs) are a class of endogenous and non-coding
single-stranded RNAs of approximately 22 nucleotides (Bartel, 2004),
many of which are evolutionarily conserved (Farh et al., 2005). Nucleo-
tides 2–7, from the 5′ end of the miRNA, are referred to as the seed se-
quence and are critical for hybridization to targets (Kim et al., 2010).
They bind to a complementary sequence of 6 to 8 base-pairs typically lo-
cated in the 3′ untranslated region (3′-UTRs) of target mRNAs. This in-
teraction either facilitates the degradation of the mRNA or delays its
translation (Kosik, 2006).alth Science Center, 76Western
i'an Jiaotong University Health
majie_article@163.com (J. Ma).
en access article under the CC BY-NCThe widespread expression and activity of miRNAs in the brain im-
plicates them in numerous neurological disorders (Cao et al., 2006).
They are emerging as key regulators of neurodevelopmental and neuro-
logical processes and dysregulation of miRNAs in developing or mature
brain, could cause pervasive changes to the molecular networks linked
to the pathophysiology of schizophrenia (Beveridge and Cairns, 2012).
MiR-137 is enriched in the dentate gyrus, a subregion of the hippocam-
pal formation that regulates adult neurogenesis and neuronal matura-
tion (Silber et al., 2008; Smrt et al., 2010). In a mega genome-wide
association study (GWAS) performed by the Psychiatric GWAS Consor-
tium (PGC), the second strongest link to schizophrenia was the genetic
variant rs1625579. This variant is located in an intron of a putative pri-
mary transcript of the MIR137 gene, which encodes miR-137 (Ripke
et al., 2011). Subsequentmulti-stage and large-scale GWA studies iden-
tiﬁedMIR137 transcript andwithin a subset of predictedmiR-137 target
genes strongly associated with schizophrenia (Ripke et al., 2013; Ripke
et al., 2014).-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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with a lifetime risk of approximately 1%; it is characterized by hallucina-
tions, delusions and cognitive deﬁcits, with heritability estimated at up
to 80% (Cardno and Gottesman, 2000; Sullivan et al., 2003). Previously,
we showed that the gene EFNB2 is associatedwith schizophrenia inHan
Chinese samples (Zhang et al., 2010). EFNB2 is located on 13q33, a re-
gion strongly linked to schizophrenia by independent genetic linkage
studies (Lin et al., 1997). It encodes amember of the protein-tyrosine ki-
nase family (ephrin), which is implicated in mediating NMDA receptor
activated regulation of development and remodeling of synaptic con-
nections (Takasu et al., 2002). EFNB2 is also an essential component of
the Reelin pathway, which controls neuronal migration during nervous
system development (Senturk et al., 2011). Using TargetScan and Mi-
randa online software and the UCSC genome browser, we found that
EFNB2 is a predicted target ofmiR-137 and that it contains a genetic var-
iant in the binding site located in the 3′-UTR of EFNB2.
A combination of literature searches, ingenuity pathway analysis
(IPA), and freely accessible bioinformatics resources identiﬁed N1000
genes predicted to interact with miR-137 (Wright et al., 2015; Wright
et al., 2013). However, few of these schizophrenia associated target
genes have been validated by biological experimentation, and even
fewer showed alterations at the protein level (Kim et al., 2012; Kwon
et al., 2013; Xia et al., 2015). In addition, Sullivan et al. showed signiﬁ-
cant gene expression similarities between whole blood and multiple
brain tissues after a through comparison of gene expression in blood
and brain (Sullivan et al., 2006). Harris et al. found that schizophrenia
could be studied using blood-based biomarkers because peripheral bio-
markers may mirror pathological processes in the brain (Harris et al.,
2012).
Therefore, we initiated a study using computational analysis, lucifer-
ase reporter assays and gene expression assays, including mRNA and
protein levels, to investigate miR-137 directly targeting EFNB2 gene
and to explore the effect of a genetic variant in the putative seed-pair re-
gion of EFNB2 3′-UTR. We also tested for the expression of miR-137 in
the peripheral blood of a cohort of ﬁrst-onset schizophrenia patients
and healthy controls to determine its potential diagnostic value.
2. Materials and Methods
2.1. Bioinformatic Analyses
TargetScan (TargetScan 6.2, http://www.targetscan.org) andMiran-
da (http://www.microrna.org) were used to predicate miR-137 and
EFNB2 interaction according to the presence of binding sites in the
seed region, the efﬁcacy of targeting and the probability of conserved
targeting (Lewis et al., 2005). The human hsa-miR-137 sequences
were obtained from miRBase (miRBase, http://www.mirbase.org).
EFNB2 mRNA 3′-UTR sequences, the location of the single nucleotide
polymorphism (SNP) rs550067317 in EFNB2 and allele frequencies
were obtained from the UCSC genome browser (http://genome.ucsc.
edu/cgi-bin/hgTracks) and NCBI database (http://www.ncbi.nlm.nih.
gov/gquery/). RNA folding structures between miRNAs and targeting
sequences and the minimum folding energy (MFE) were predicted by
RNAhybrid (http://bibiserv.techfak.uni-bielefeld.de/rnahybrid)
(Kruger and Rehmsmeier, 2006; Rehmsmeier et al., 2004).
2.2. Vector Construction and Sequence Mutagenesis
A 500-bp-long 3′-UTR fragment of the EFNB2 gene containing the
putativemiR-137 binding site was synthesized by GenePharm Corpora-
tion. The sequence was cloned into the pmirGLO luciferase vector
(Promega, USA) downstream of the ﬁreﬂy luciferase coding region, be-
tween the SacI and XbaI sites. The DNA sequences of the ampliﬁed frag-
ments were identiﬁed by restriction enzyme digestion and sequencing
and were consistent with the RCh38/hg38 reference sequence from
UCSC. This vector was referred to as the wild type or rs550067317(A) vector. The mutated EFNB2 3′-UTR sequences, containing all six nu-
cleotides in the putative seed-pair region, was synthesized according to
A-T, C-G substitution criteria. PCR-directedmutationwas used to gener-
ate a mutation of minor allele C of SNP rs550067317. Likewise, these
two mutations were cloned into the pmirGLO vector and referred to
as full mutant and rs550067317(C) vector respectively. Both of them
are validated by two methods of restriction enzyme digestion and se-
quencing. The primer information for the gene 3′-UTR to construct dif-
ferent vectors are showed in Table 1. In addition, the ZNF804A 3′-UTR
was synthesized, and the pmirGLO + ZNF804A was constructed as a
positive control.
2.3. Cell Culture
HEK293T and SH-SY5Y cell linesweremaintained at 37 °Cwith a hu-
midiﬁed atmosphere of 5% CO2. HEK293T cells were cultured in
Dulbecco's modiﬁed Eagle medium and high glucose medium
(DMEM/HIGH GLUCOSE) (Hyclone, USA) supplemented with 10% fetal
bovine serum (FBS) (Gibco, Australia), 100 U/mL penicillin, and
100 μg/mL streptomycin (Penicillin-Streptomycin Solution) (Hyclone,
USA). SH-SY5Y cells were cultured in DMEM:Nutrient Mixture F-12
containing 1.5 mM L-glutamine at a ratio of 1:1 (DMEM/F-12) supple-
mented with 10% FBS, 100 U/mL of penicillin, and 100 μg/mL of
streptomycin.
2.4. Dual Luciferase Reporter Assay
Luciferase reporter constructs were transfected into HEK293T cell.
The mature miR-137 sequence (miR-137 mimics) and negative control
miRNAs (mimic NC) were ordered from GenePharm Corporation. The
combination of miR-137 mimics and pmirGLO + ZNF804A was co-
transfected into SH-SY5Y cells as a positive control. To test for an inter-
action betweenmiR-137 and the EFNB2 3′-UTR, combinations ofmimics
or NC with full mutant and wild type/rs550067317(A) were co-
transfected respectively andwere harvested after 24 h or 48 h. To deter-
mine whether rs550067317(C) affects the inhibition, we tested combi-
nations of miR-137 or NC with different constructs and harvested after
24 h. The activity of the luciferase reporter gene was detected using
the Dual-Luciferase® Reporter Assay System (Promega, USA). Each
sample was tested in triplicate and the relative luciferase activity was
calculated as the ratio of ﬁreﬂy to Renilla luciferase activity and normal-
ized against a blank control.
2.5. RNA Isolation and Real-Time Quantitative PCR (RT-qPCR)
SH-SY5Y cells were transfected with miR-137 mimics or with NC.
For comparison, we generated a blank control using the same volume
ofmedia and amock control using the same volume ofmedia and trans-
fection reagents. Samples for each group were transfected in triplicate.
Twenty-four hours after transfection, total RNA was extracted with
TRIzol® (Invitrogen, USA) and quantiﬁed by NanoDrop2000 (Thermo,
USA). The ﬁrst strand of cDNA for miRNA was synthesized using Mir-X
miRNA First-Strand Synthesis Kit (Clontech, USA), and the ﬁrst strand
for mRNA was synthesized using RevertaidTM First Strand cDNA Syn-
thesis kit (Fermentas, Canada). Real-time quantitative PCR (RT-qPCR)
was performed with the FastStart Universal SYBR Green Master (Rox)
(Roche, USA) for quantiﬁcation. Gene and miRNA expression were nor-
malized by GAPDH and U6 small nuclear RNA (snRNA), respectively.
Each sample was tested in three repeats and all data were analyzed
using the 2-ΔΔCt method. The primer information for genes and RNAs
was shown in Table 1.
2.6. Protein Isolation and Western Blotting
Forty-eight hours after transfection with four groups, the SH-SY5Y
cells were washed with cold PBS and lysed in RIPA Lysis Buffer
Table 1
Primer information for genes and small RNAs.
Gene name Accession
number
Primer Location for the ﬁrst nucleotide of
the
primera
Sequence (from 5′ to 3′) Annealing
temperature
(°C)
EFNB2 NM_004093 Forward for RT-qPCR Chr13:106,494,962 GATCCAACAAGACGTCCAGAA 60
Reverse for RT-qPCR Chr13:106,493,342 CTGAAGCAATCCCTGCAAATA
3′-UTR Forward for mutationb Chr13:106,492,317 CGAGCTCAGTGGGGCTGGGGAAAGGGCT 58
3′-UTR Reverse for mutationb Chr13:106,491,818 GCTCTAGATGACCTTTGGCTTTTCAAC
rs550067317(C) Forward for
mutation
Chr13:106,491,988 TACTGGCACTAAGATACACAGCTCCGAG
CT
58
rs550067317(C) Reverse for mutation Chr13:106,491,972 GTATCTTAGTGCCAGTACCACAACAGTC
CT
GAPDH NM_002046 Forward for RT-qPCR Chr12:6,537,347 CCAAGGTCATCCATGACAACT 60
Reverse for RT-qPCR Chr12:6,537,683 CAGGGATGATGTTCTGGAGAG
Hsa-miR-137 NR_029679 Forward for RT-qPCR Chr1:98,046,113 TTATTGCTTAAGAATACGCGTAG 60
U6 snRNA NR_004394 Forward for RT-qPCR Chr15:67,840,042 CTCGCTTCGGCAGCACA 60
Reverse for RT-qPCR Chr15:67,839,949 AACGCTTCACGAATTTGCGT
a UCSC Browser, Dec. 2013; http://genome,ucsc.edu/cgi-bin/hgGateway.
b Several nucleotides (restriction enzyme cutting site) have been added to the 5′ terminal of the primer.
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bicinchonininc acid (BCA) assay kit (Pierce, USA). On a 10% SDS-PAGE
gel, the total protein was separated and transferred to a PVDF mem-
brane (Millipore, USA). GAPDH on the same membrane was used as a
loading control. The primary monoclonal antibodies were anti-EFNB2
(ab150411, Abcam, UK) or anti-GAPDH (TA-08, ZSGB-BIO, China) and
anti-mouse (31430, Thermo, USA) or anti-rabbit IgG (31460, Thermo,
USA)were used as the secondary antibodies to further detect the signal.
The target proteins were determined on membranes by an enhanced
chemiluminescence system (Millipore, USA). The intensities of the im-
munoblots were quantiﬁed with a bio imaging (Syngene, UK) coupled
to a personal computer. Expression level was accomplished by
obtaining the ratio of the band density of EFNB2 to that of GAPDH
from the same sample.
2.7. Peripheral Blood Collection and RT-qPCR
All subjects were Han Chinese in origin and from Northwest China.
All patients were independently diagnosed by at least two experienced
psychiatrists according to theDiagnosis and StatisticalManual ofMental
Disorders Fourth Edition (DSM-IV) criteria for schizophrenia. A total of
88 unrelated individuals were recruited from the Northwest China
that included 44 patients (22 males, mean age = 28.45 ± 6.79 years;
22 females, mean age = 30.73 ± 7.67 years) with schizophrenia and
44 healthy controls (22 males, mean age = 30.22 ± 4.22 years; 22 fe-
males, mean age = 30.36 ± 7.59 years). All patients were drug naive
and untreated from any other methods. Controls were drawn from un-
related volunteers and blood donors. Any individuals with current or
past evidence ofmental illness or a relativewithmental illness were ex-
cluded from the study. The study was approved by the medical ethics
committee of Xi'an Jiaotong University Health Science Center and in-
formed consent was obtained from all subjects.
Peripheral blood samples from the participants were collected in
EDTA tubes and placed on ice. Within 2 h, total RNA was harvested
using TRIzol® (Invitrogen, USA) according to the manufacturer's instruc-
tions and quantiﬁed using a NanoDrop 2000 (Thermo, USA). Reverse
transcription and RT-qPCR for the mRNA expression were performed as
previously described for SH-SY5Y cells. Furthermore, GAPDH, ATCB and
B2M were selected as multiple internal control genes in peripheral
blood samples according to the complexity of blood components, and
the geometric mean of the three control genes was used to normalize
the expression of EFNB2 (Vandesompele et al., 2002).
2.8. Statistical Analyses
All data are presented as the mean ± standard error of the mean
(SEM). Statistically signiﬁcant differences between groups werecalculated using an analysis of variance. The results within a group
were evaluated using the student's t-test. For the data that did not ﬁt
the normal distribution and homogeneity of variance, the non-
parametric test was performed. The receiver operating characteristics
(ROC) curve was constructed to determine the sensitivity, speciﬁcity
and area under curve (AUC) for miR-137 levels in peripheral blood.
Data analyses were performed using GraphPad Prism 5 software
(GraphPad Co. Ltd., San Diego, CA, USA) or SPSS software version 18.0
(SPSS, Inc., Chicago, IL, USA). Differences with P-values of b0.05 were
considered statistically signiﬁcant.
3. Results
3.1. Bioinformatic Prediction of EFNB2 as a miR-137 Target, and Different
Allele of SNP rs550067317 within EFNB2 Affects the MFE
The TargetScan and Miranda online software predicted that hsa-
miR-137 was a candidate miRNA for targeting the EFNB2 gene at nucle-
otides 1057–1063 of its 3′-UTR. The complementary sequence was
shown in Fig. 1A, with themiR-137 seed sequence shown in red. The se-
quence in the binding site of EFNB2 3′-UTR was broadly conserved
among vertebrates, including human, rhesus, dog, elephant and chick-
en, suggesting its potential important function for the gene (Fig. 1B).
The SNP rs550067317 is in the EFNB2 3′-UTR binding site for miR-
137 and theminor allele is the nucleotide C (Fig. 1C).With themajor al-
lele A at rs550067317, base-pairing between EFNB2 3′-UTR mRNA and
mature miR-137 results in a typical stem-loop structure essential for
miRNA-mediated expression repression. When the minor allele of C is
present at rs550067317, it disrupts the formation of the stem in this es-
sential structure. With the minor allele, the MFE increases to
−12.9 kcal/mol, compared with an MFE of −16.6 kcal/mol for the
major allele A, indicating decreased stability in the secondary RNA fold-
ing structure (Fig. 1D).
3.2. Full Mutant and rs550067317(C) Vector in the Binding Site of EFNB2
3′-UTR Independently Reverses the Inhibition of miR-137 in Luciferase Ac-
tivity Assays
All constructed vectors were validated by restriction enzyme diges-
tion and sequencing methods (Fig. 2). Data for pmirGLO + ZNF804A
were not shown. The constructs of full mutant and rs550067317
(C) vector were shown on Fig. 3A.
As shown in Fig. 4, luciferase activity in HEK293T cells co-transfected
with miR-137 mimics and pmirGLO + ZNF804A was signiﬁcantly de-
creased compared with NC and the reporter gene construct, which
was consistent with the previous reports (Kim et al., 2012; Xia et al.,
2015). Fig. 3B and C showed that the luciferase activity in cells co-
Fig. 1. EFNB2 as target of miR-137, and different allele of SNP rs550067317 affects the MFE. A. Schematic diagram of the pairing relationship between miR-137 and EFNB2mRNA 3′-UTR
analyzed by TargetScan andMiranda online software. The putative seed-pair regionwas in red. B. Broad conservation of the target sites in EFNB2 3′-UTR among vertebrates. C. The location
of SNP rs550067317 in EFNB2 3′-UTR binding site. D. Location of the SNP rs550067317 alleles.
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signiﬁcantly decreased after 24 h and 48 h compared with mimics and
full mutated vector. In the group of NC, there was no signiﬁcant differ-
ence in luciferase activity, suggesting that miR-137 directly binds to
the EFNB2 3′-UTR and inhibits its expression. In Fig. 3D, the luciferase
activity decreased signiﬁcantly in the group of co-transfection of miR-
137 mimics and wild type, causing 36% reduction compared with the
full mutant, and 29% reduction compared with the rs550067317
(C) vector, while the luciferase activity did not differ signiﬁcantly withthe combinations of NC and the different constructs, suggesting that
SNP rs550067317 (C) also disrupted themiR-137-mediated repression.
Luciferase activity in cells co-transfectedwith a combination ofmiR-137
with the full mutant and the rs550067317 (C) vector did not show sig-
niﬁcant differences, suggesting that the minor allele of SNP
rs550067317 reverses the inhibition independently. The decreased ef-
fect of rs550067317(C) was consistent with in silico analyses of the
SNP effect on RNA-folding structures formed by miR-137 and its target
sequence in EFNB2 (Fig. 1D).
Fig. 2.The results of restriction enzymedigestion and sequencing. A. The results of restriction enzymedigestion. Lane1 shows themarker ofD2000, lanes 2–4 shows the restriction enzyme
digestion result of wild type/rs550067317(A), full mutant, rs550067317(C) construct, respectively. B, C, D. The sequencing result of wild type/rs550067317(A), full mutant,
rs550067317(C) construct, respectively.
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in SH-SY5Y Cells
Reporter gene assayswere used to conﬁrm the direct targeting of the
miR-137 to the 3′-UTR of EFNB2. To determine whether endogenously
expressed EFNB2 is subject to regulation by miR-137, miR-137 mimics
and the negative control were transfected into SH-SY5Y cells, a neuro-
blastoma cell line commonly used in the study of schizophrenia. The
RT-qPCR results of miRNA expression showed that miR-137 mimics
caused mature miR-137 levels to increase by N2000-folds compared
with NC, mock or control, conﬁrming the transfection efﬁciency (Fig.
5A). Analyses ofmRNAexpression show thatmiR-137has no signiﬁcant
effect on the stability or expression level of EFNB2 mRNA (Fig. 5B).
Western blots indicated that miR-137 mimics were able to decrease
the EFNB2 protein level compared with the NC, mock or control (Fig.
5C). Three independent western blotting experiments were performed
and the relative expression of EFNB2 was signiﬁcantly decreased (Fig.
5D). These data suggest that endogenous EFNB2 expression is down-
regulated by miR-137 at the protein level.3.4. MiR-137 Is aberrantly Expressed in Peripheral Blood of Schizophrenia
Patients and Has some Diagnostic Value for the Disease
The age distribution of samples was shown in Fig. 6A. In the periph-
eral blood of schizophrenia patients, there was a signiﬁcant increase of
2.63-fold in the expression of miR-137 compared with healthy controls
(Fig. 6B). Expression of the target gene, EFNB2, was not signiﬁcantly al-
tered (Fig. 6C). The relationship between miR-137 and EFNB2 mRNAexpression levels was consistent with data obtained using SH-SY5Y
cells. Because miR-137 was aberrantly expressed in the peripheral
blood of schizophrenia patients, we performed a receiver operating
characteristics (ROC) curve analysis to evaluate the diagnostic value of
miR-137 in differentiating between patients with schizophrenia and
healthy controls. As shown in Fig. 6D, the area under the curve (AUC)
of miR-137was 0.795 (95% conﬁdence interval 0.700–0.890), the sensi-
tivity of the cut-off pointwas 70.5%, and the speciﬁcity was 84.1%. These
results suggested that miR-137 in peripheral blood has certain diagnos-
tic value for schizophrenia.
4. Discussion
Although genome-wide association studies provide a systematic,
powerful, and unbiasedmethod for studying the common disease/com-
mon variant (CDCV) hypothesis of complex disorders such as schizo-
phrenia, the identiﬁcation of susceptibility loci for schizophrenia was
not replicated across studies because of the genetic heterogeneity of
schizophrenia among different populations (Shi et al., 2011; Yue et al.,
2011). Nonetheless, a robust statistical association between the
MIR137 gene and schizophrenia identiﬁed in Europeans through
genome-wide association studies was replicated in the Han Chinese
population in a case-control study (Guan et al., 2014; Ripke et al.,
2011; Ripke et al., 2013; Ripke et al., 2014). The type ofmiR-137 seed se-
quence was canonical and the sequence of binding site within EFNB2
were evolutionary conserved (Bartel, 2009). Using a computational pre-
diction analysis and report gene assays, EFNB2 gene was directly
targeted bymiR-137. Furthermore, in our previous study of EFNB2 asso-
ciated with schizophrenia, all the samples were recruited from
Fig. 3.MiR-137 directly targets EFNB2 gene and SNP rs550067317(C) independently reverses the inhibition. A. Schematic diagram of three different constructs. The arrow marked the
minor allele C in the construct. B, C. Dual luciferase reporter assay of miR-137 mimics/negative co-transfected with full mutant and wild type construct in HEK293T cells after 24 h and
48 h. D. Dual luciferase reporter assay of miR-137 mimics/negative co-transfected with full mutant, rs55006731(C), and wild type construct in HEK293T cells. Bars represent SEM from
three experiments. NC, negative control. ** indicates P b 0.01, *** indicates P b 0.001.
138 S. Wu et al. / EBioMedicine 12 (2016) 133–142
Fig. 4. The dual luciferase reporter assay ofmiR-137mimics/negative co-transfectingwith
PmirGLO + ZNF804A in HEK293T cells. 24 h after transfection, the cells were assayed for
ﬁreﬂy luciferase activity and Renilla luciferase activity test and the ratio of ﬁreﬂy/Renilla is
obtained. Bars represent SEM from three experiments. NC, negative control. ** indicates
P b 0.01.
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neity is helpful to ﬁnd some susceptibility loci, especially that might in-
crease susceptibility to the disease in a subpopulation.
Both EFNB2 and DAOA genes involved in NMDA receptor signaling-
mediated susceptibility to schizophrenia have been identiﬁed in a Han
Chinese population in our previous studies (Ma et al., 2006; Zhang
et al., 2010). Interestingly, a recent genome-wide association analysisFig. 5.MiR-137 inhibits endogenous expression of EFNB2 at protein level. A. RT-qPCR results of
expression SH-SY5Y cells. C.Western blotting results of EFNB2 andGAPDHas an internal control
kit. D. Statistical analysis of Western blotting results from three independent western blottingidentiﬁed 13 new risk loci for schizophrenia and suggested the involve-
ment of glutamatergic neurotransmission signaling in the etiology of
schizophrenia, providing robust support for the association of NMDA re-
ceptor signaling with schizophrenia (Ripke et al., 2014). Sentürk et al.
reported that the activation of ephrin Bs, including EFNB2,was sufﬁcient
to rescue the absence of Reelin (Senturk et al., 2011). Reelin signaling
was required for the nervous system to function properly, and disrup-
tion of this pathway results in lissencephaly, a severe developmental
disorder associated with schizophrenia (Costa et al., 2002; Herz and
Chen, 2006; Hong et al., 2000). Previous studies have demonstrated
that miR-137 regulates adult neurogenesis, neuronal maturation, and
presynaptic plasticity (Siegert et al., 2015; Silber et al., 2008; Smrt
et al., 2010; Szulwach et al., 2010). Siegert et al. showed that overex-
pression of miR-137 caused impairment in synaptic vesicle trafﬁcking
and alterations in synaptic plasticity (Siegert et al., 2015). Using meta
gene set enrichment analyses, Wright et al. found that potential target
gene sets of miR-137 were enriched with variants associated with
Ephrin receptor signaling and some other signal pathways (Wright
et al., 2015). In current study, we provided the molecular experimental
evidence to validate EFNB2 as a direct target of miR-137, including dual
luciferase reporter gene assays and western blotting methods per-
formed in two cell lines, suggesting that miR-137 as a risk factor in
schizophrenia, might be implicated in NMDA receptor signaling and/
or Reelin signaling pathway.
It was more intriguing that the SNP rs550067317 lies in the binding
site in EFNB2 3′-UTR and rs550067317(C) is a genetic variant. The cur-
rent study conﬁrmed that the rs550067317(C) vector reversed the re-
pression of luciferase activity caused by miR-137, validating this SNP
is a functional genetic variant. The functional genetic variant may also
have implications in understanding the genetic architecture ofmiR-137 relative expression in SH-SY5Y cells. B. RT-qPCR results of EFNB2mRNA relative
. The band size of EFNB2 is 50 kDawhich is consistentwith the speciﬁcation of the antibody
experiments. NC, negative control. * indicates P b 0.05, ***indicates P b 0.001.
Fig. 6. MiR-137 is aberrantly expressed in peripheral blood of schizophrenia patients. A. The distribution of sample ages. B. The expression of miR-137 in the peripheral blood of
schizophrenia patients and healthy controls. C. The expression of EFNB2 in the peripheral blood of schizophrenia patients and normal controls. D. Receiver operating characteristic
(ROC) curve analysis of the diagnostic value of miR-137 expression for schizophrenia. CON, normal control; SCH, schizophrenia patients; AUC, area under curve. ***indicates P b 0.001.
140 S. Wu et al. / EBioMedicine 12 (2016) 133–142schizophrenia. The predominant hypothesis in recent years has been
that as in other common diseases, the genetic architecture of schizo-
phrenia involves the action of numerous common alleles with small to
moderate effects and possibly some rare alleles withmuch larger effects
(Wang et al., 2005;Williams et al., 2009). It is not contradictory to have
both common and rare variants as the genetic basis of a complex trait
such as schizophrenia; the effects of both classes can be readily recon-
ciled (Gibson, 2012;McCarthy et al., 2008; Owen et al., 2010). In studies
of schizophrenia, people are categorized as cases or controls. However,
the genetic contributions are complex, and the schizophrenia generally
displays a threshold-dependent response superimposed on a continu-
ous liability composed of many variants. A rare variant can either in-
crease or decrease function, and its association with the disease will
be conditional on the patient's background liability (Gibson, 2012).
The SNP rs550067317 is a rare variant. The minor allele C is only exist
in Northern Han Chinese population (Beijing, CHB) and the frequency
is 0.97% according to the present data base (http://www.ncbi.nlm.nih.
gov/variation/tools/1000genomes/?q=rs550067317). The current
study demonstrated that the minor allele of rs550067317 reversed the
inhibition of miR-137 similar to the full mutation in the binding sites
of EFNB2 3’UTR. Itmight strengthen EFNB2 function by impairing the di-
rect interaction of miR-137 with EFNB2 in conditions where miR-137 is
aberrantly overexpressing.
To determine if the overexpression of miR-137 negatively regulate
EFNB2 expression, human neuroblastoma SH-SY5Y cells were
transfected with mature miR-137 sequences or negative control
miRNAs. The results showed that the overexpression of miR-137 did
not affect the mRNA expression of EFNB2 but signiﬁcantly repressed
the accumulation of EFNB2 protein. This post-transcriptional function
was consistent with initial discovery of animal miRNA, which inhibitedprotein synthesis and preserved the stability of the mRNA target
(Ambros, 2004; Olsen and Ambros, 1999; Seggerson et al., 2002). Simi-
larly,we demonstrated that in theperipheral blood ofﬁrst-onset schizo-
phrenia patients compared with healthy controls, the expression of
miR-137 was signiﬁcantly increased, and the mRNA levels of EFNB2
were not signiﬁcantly different.
We used the conventional ROC curve ofmiR-137 in peripheral blood
to calculate the area under the curve (AUC) with 95% conﬁdence inter-
vals. The AUC reached 0.795, indicating that miR-137 has certain value
for diagnosing schizophrenia. Schizophrenia is a chronic, frequently dis-
abling mental disorder with neurodevelopmental impairment (Insel,
2010). In both the neurodevelopment and the etiology of psychiatric
disease such as schizophrenia, miRNA plays a pivotal role (Miller and
Wahlestedt, 2010;Welberg, 2010; Xu et al., 2010). Because brain tissue
is not readily accessible, blood-based expression proﬁling of miRNAs is
increasingly common for the discovery of pathophysiology and identiﬁ-
cation of potential biomarkers for schizophrenia (Lai et al., 2011; Yu
et al., 2015; Zhang et al., 2014). A major advantage of blood sample is
avoiding potential changes inmiRNA levels by different processing con-
ditions (Cheng et al., 2013). The current study also showed that miR-
137 in peripheral blood is a potential biomarker for differentiating be-
tween schizophrenia patients and healthy controls.
It is important to note that although the rare SNP rs550067317 in
EFNB2 gene was not genotyped in a large population and the frequency
of the minor allele C in the patients of schizophrenia and healthy con-
trols was unknown, but we uncovered that it is a functional genetic var-
iant through pointmutation and dual luciferase activity assay. The other
limitation of the current study is that TaqMan method for quantifying
gene expressionmight bemore sensitive than SYBR. However, the latter
is widely accepted and applied to many studies.
141S. Wu et al. / EBioMedicine 12 (2016) 133–1425. Conclusion
We provided strong experimental evidence that miR-137 directly
down-regulates the expression of EFNB2, and a genetic variant in the
RNA binding site in EFNB2 gene affects the expression regulation. MiR-
137, as a risk factor for schizophrenia, might be implicated in NMDA re-
ceptor signaling and/or Reelin signalingpathway. Further clinical exper-
iment in peripheral blood veriﬁed that miR-137 is aberrantly expressed
in the ﬁrst-onset patients of schizophrenia compared healthy controls
and it has certain diagnostic value for the disease. This study not only
improved the understanding of the roles of EFNB2 and the genetic
basis of rs550067317 for schizophrenia, but also provided new evi-
dences for miR-137 involved in schizophrenia etiology and diagnosis,
which might contribute to discover new biomarkers and therapeutic
targets for the disease.
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